Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 6/2012

01.08.2012 | Beiträge zum Themenschwerpunkt

Challenges and opportunities in the design of age-appropriate drug products

verfasst von: S. Stegemann

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

The age appropriateness of a pharmaceutical product for older patient populations is most important in achieving ease of use, administration, and adherence as well as the therapeutic benefit of the drug. Drug development is a lengthy and risky investment accompanied by extensive regulatory requirements to meet all the safety, efficacy, and quality criteria of a pharmaceutical product. Older adults represent a very heterogeneous patient population with different needs compared to younger adults. Major areas that should be considered in the design of age-appropriate products (AAP) are age- and disease-related aspects such as (a) different dose strengths, (b) issues in handling, administering, and managing the drug product, (c) and complex medication regimens. The application of different technologies can meet these specific needs and should be considered at the very beginning of product development when setting the targeted quality product profile (TQPP) or later on during the product life-cycle management.
Literatur
1.
Zurück zum Zitat Jaruzelski B, Loehr J, Holman R (2011) The global innovation 1000: why culture is key. Booz & Co Report 65 Jaruzelski B, Loehr J, Holman R (2011) The global innovation 1000: why culture is key. Booz & Co Report 65
2.
Zurück zum Zitat DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185PubMedCrossRef DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185PubMedCrossRef
3.
Zurück zum Zitat (o A) (2010) Pharmaceutical key trends 2010. Report DMHC2599, Datamonitor (o A) (2010) Pharmaceutical key trends 2010. Report DMHC2599, Datamonitor
4.
Zurück zum Zitat Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715PubMedCrossRef Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715PubMedCrossRef
6.
Zurück zum Zitat Kneller R (2010) The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 9:867–882PubMedCrossRef Kneller R (2010) The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 9:867–882PubMedCrossRef
7.
Zurück zum Zitat Snow V, Barry P, Fihn SD et al (2004) Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American college of physicians. Ann Intern Med 141:562–567PubMed Snow V, Barry P, Fihn SD et al (2004) Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American college of physicians. Ann Intern Med 141:562–567PubMed
8.
Zurück zum Zitat Maas J, Kamm W, Hauck G (2007) An integrated early formulation strategy – from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66:1–10PubMedCrossRef Maas J, Kamm W, Hauck G (2007) An integrated early formulation strategy – from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66:1–10PubMedCrossRef
9.
Zurück zum Zitat Hoffman AS (2008) The origin and evolution of “controlled” drug delivery systems. J Contr Rel 132:153–163CrossRef Hoffman AS (2008) The origin and evolution of “controlled” drug delivery systems. J Contr Rel 132:153–163CrossRef
10.
Zurück zum Zitat Swain S, Beg S, Singh A et al (2011) Advanced techniques for penetration enhancement in transdermal drug delivery systems. Curr Drug Deliv 8(4):456–473PubMedCrossRef Swain S, Beg S, Singh A et al (2011) Advanced techniques for penetration enhancement in transdermal drug delivery systems. Curr Drug Deliv 8(4):456–473PubMedCrossRef
11.
Zurück zum Zitat Hohenegger M (2010) Novel and current treatment concepts using pulmonary drug delivery. Curr Pharm Design 16:2484–2492CrossRef Hohenegger M (2010) Novel and current treatment concepts using pulmonary drug delivery. Curr Pharm Design 16:2484–2492CrossRef
12.
Zurück zum Zitat Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9(4):384–398PubMedCrossRef Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9(4):384–398PubMedCrossRef
13.
Zurück zum Zitat Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41(2):67–76PubMedCrossRef Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41(2):67–76PubMedCrossRef
14.
Zurück zum Zitat Bushardt RL, Massey EB, Simpson TW et al (2008) Polypharmacy: misleading, but manageable. Clin Interv Aging 3(2):383–389PubMed Bushardt RL, Massey EB, Simpson TW et al (2008) Polypharmacy: misleading, but manageable. Clin Interv Aging 3(2):383–389PubMed
15.
Zurück zum Zitat Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncolo Hematol 48:133–143CrossRef Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncolo Hematol 48:133–143CrossRef
16.
Zurück zum Zitat Rodenhuis N, De Smet PAGM, Barends DM (2004) The rational of scored tablets as dosage form. Eur J Pharm Sci 21:305–308PubMedCrossRef Rodenhuis N, De Smet PAGM, Barends DM (2004) The rational of scored tablets as dosage form. Eur J Pharm Sci 21:305–308PubMedCrossRef
17.
Zurück zum Zitat (o A) (2009) FDA Tablet splitting: a risky practice. 21. July 2009 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm171492.htm (o A) (2009) FDA Tablet splitting: a risky practice. 21. July 2009 http://​www.​fda.​gov/​ForConsumers/​ConsumerUpdates/​ucm171492.​htm
18.
Zurück zum Zitat Quinzler R, Gasse C, Schneider A et al (2006) The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 62:1065–1073PubMedCrossRef Quinzler R, Gasse C, Schneider A et al (2006) The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 62:1065–1073PubMedCrossRef
19.
Zurück zum Zitat Atkin PA, Finnegan TP, Ogle SJ, Shenfield GM (1994) Functional ability of patients to manage medication packaging: a survey of geriatric inpatients. Age Ageing 23:113–116PubMedCrossRef Atkin PA, Finnegan TP, Ogle SJ, Shenfield GM (1994) Functional ability of patients to manage medication packaging: a survey of geriatric inpatients. Age Ageing 23:113–116PubMedCrossRef
20.
Zurück zum Zitat Lee JK, Grace KA, Taylor AJ (2006) Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA 296(21):2563–2571PubMedCrossRef Lee JK, Grace KA, Taylor AJ (2006) Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA 296(21):2563–2571PubMedCrossRef
21.
Zurück zum Zitat Klaver CW, Wolfs RCW, Vingerling JR et al (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population. Arch Ophathalmol 116:653–658 Klaver CW, Wolfs RCW, Vingerling JR et al (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population. Arch Ophathalmol 116:653–658
22.
Zurück zum Zitat Wijk H, Berg S, Bergman B et al (2002) Colour perception among the very elderly related to visual and cognitive function. Scand J Caring Sci 16:91–102PubMedCrossRef Wijk H, Berg S, Bergman B et al (2002) Colour perception among the very elderly related to visual and cognitive function. Scand J Caring Sci 16:91–102PubMedCrossRef
23.
Zurück zum Zitat Hersberger J (1997) Differenzierbarkeit und Präferenz von Kapselfarben bei älteren Menschen. Lizentiatsarbeit Universität Basel, Institut für Psychologie, November 1997 Hersberger J (1997) Differenzierbarkeit und Präferenz von Kapselfarben bei älteren Menschen. Lizentiatsarbeit Universität Basel, Institut für Psychologie, November 1997
24.
Zurück zum Zitat Perrig JW, Wippich W, Perrig-Chiello P (1993) Unbewußte Informationsbearbeitung. Verlag Hans Huber, Bern Perrig JW, Wippich W, Perrig-Chiello P (1993) Unbewußte Informationsbearbeitung. Verlag Hans Huber, Bern
25.
Zurück zum Zitat Perrig-Chiello P, Perrig JW, Staehelin H et al (1994) IDA-Die Basler Interdisziplinäre Altersstudie Perrig-Chiello P, Perrig JW, Staehelin H et al (1994) IDA-Die Basler Interdisziplinäre Altersstudie
26.
Zurück zum Zitat Stegemann S (2005) Colored capsules – a contribution to drug safety. Pharm Ind 67(9):1088–1095 Stegemann S (2005) Colored capsules – a contribution to drug safety. Pharm Ind 67(9):1088–1095
27.
Zurück zum Zitat Stegemann S, Gosch M, Breitkreutz J (o J) Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm (in press) Stegemann S, Gosch M, Breitkreutz J (o J) Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm (in press)
28.
Zurück zum Zitat Kottke MK, Stetsko G, Rosenbaum SE, Rhodes CT (1990) Problems encountered by the elderly in the use of conventional dosage forms. J Geriatr Drug Ther 5(2):77–92 Kottke MK, Stetsko G, Rosenbaum SE, Rhodes CT (1990) Problems encountered by the elderly in the use of conventional dosage forms. J Geriatr Drug Ther 5(2):77–92
29.
Zurück zum Zitat Payot V, Cordonier A-C, Marquis J et al (2011) Prevalence of patients’ difficulties in swallowing solid SODF. Int J Clin Pharm 33:402 Payot V, Cordonier A-C, Marquis J et al (2011) Prevalence of patients’ difficulties in swallowing solid SODF. Int J Clin Pharm 33:402
30.
Zurück zum Zitat Paradiso LM, Roughead EE, Gilbert AL et al (2002) Crushing or atering medications: what’s happening in residential aged-care facilities? Aust J Ageing 21(3):123–127CrossRef Paradiso LM, Roughead EE, Gilbert AL et al (2002) Crushing or atering medications: what’s happening in residential aged-care facilities? Aust J Ageing 21(3):123–127CrossRef
31.
Zurück zum Zitat Strachan I, Greener M (2005) Medication related swallowing difficulties may be more common than we realize. Pharm Pract 15(10) 411–414 Strachan I, Greener M (2005) Medication related swallowing difficulties may be more common than we realize. Pharm Pract 15(10) 411–414
32.
Zurück zum Zitat Clave P, Arreola V, Romea M et al (2008) Accuracy of the volume viscosity swallow test for clinical screening of oropharyngeal dysphagia and aspiration. Clin Nutri 27:806–815CrossRef Clave P, Arreola V, Romea M et al (2008) Accuracy of the volume viscosity swallow test for clinical screening of oropharyngeal dysphagia and aspiration. Clin Nutri 27:806–815CrossRef
33.
Zurück zum Zitat Spomer N, Klingmann V, Stoltenberg I et al (2012) Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 97:283–286PubMedCrossRef Spomer N, Klingmann V, Stoltenberg I et al (2012) Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 97:283–286PubMedCrossRef
34.
Zurück zum Zitat Metz DC, Vakily M, Dixit T, Mulford D (2009) Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pumb inhibitor therapy. Aliment Pharmacol Ther 29:928–937PubMedCrossRef Metz DC, Vakily M, Dixit T, Mulford D (2009) Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pumb inhibitor therapy. Aliment Pharmacol Ther 29:928–937PubMedCrossRef
35.
Zurück zum Zitat Carneby-Mann G, Crary M (2005) Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 131(11):970–975CrossRef Carneby-Mann G, Crary M (2005) Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 131(11):970–975CrossRef
36.
Zurück zum Zitat Breitkreutz J, Boos J (2007) Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 4(1):37–45CrossRef Breitkreutz J, Boos J (2007) Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 4(1):37–45CrossRef
37.
Zurück zum Zitat Geriatric Medicine Society (2011) Expert meeting on geriatric medicines. March 16, 2011 http://www.geriatric-medicine.org/images/downloads/gme_meeting20110311.pdf Geriatric Medicine Society (2011) Expert meeting on geriatric medicines. March 16, 2011 http://​www.​geriatric-medicine.​org/​images/​downloads/​gme_​meeting20110311.​pdf
38.
Zurück zum Zitat Guidance for Industry: container closure systems for packaging human drugs and biologics. FDA May 1999 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070551.pdf Guidance for Industry: container closure systems for packaging human drugs and biologics. FDA May 1999 http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​ucm070551.​pdf
39.
Zurück zum Zitat Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364(11):985–987PubMedCrossRef Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364(11):985–987PubMedCrossRef
Metadaten
Titel
Challenges and opportunities in the design of age-appropriate drug products
verfasst von
S. Stegemann
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 6/2012
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-012-0361-z

Weitere Artikel der Ausgabe 6/2012

Zeitschrift für Gerontologie und Geriatrie 6/2012 Zur Ausgabe

Beiträge zum Themenschwerpunkt

Polypharmacy and incontinence

Mitteilungen der DGGG

Mitteilungen der DGGG

Beiträge zum Themenschwerpunkt

Osteoporosis and polypharmacy